In this Forbes Q&A, Matthew Herper interviews James Thomson, who's recently started his own company, Cellular Dynamics International, which is focused on testing experimental drugs for heart side effects. Rather than cave into the hype surrounding regenerative medicine, he sees much bigger opportunities for stem cells as a research tool and in drug discovery.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.